SRR1439807
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.434
- MYOGENESIS+0.330
- PANCREAS_BETA_CELLS+0.314
- HEDGEHOG_SIGNALING+0.278
- SPERMATOGENESIS+0.235
- APICAL_JUNCTION+0.144
- APICAL_SURFACE+0.120
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.110
- ESTROGEN_RESPONSE_LATE+0.090
- ESTROGEN_RESPONSE_EARLY+0.080
Top 10 suppressed
- MYC_TARGETS_V1-0.544
- IL6_JAK_STAT3_SIGNALING-0.504
- PROTEIN_SECRETION-0.494
- E2F_TARGETS-0.487
- G2M_CHECKPOINT-0.446
- TGF_BETA_SIGNALING-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.432
- TNFA_SIGNALING_VIA_NFKB-0.423
- INTERFERON_GAMMA_RESPONSE-0.399
- MTORC1_SIGNALING-0.391
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1392985 | GTEX | — | 0.980 |
| 2 | SRR1480988 | GTEX | — | 0.972 |
| 3 | SRR1466993 | GTEX | — | 0.970 |
| 4 | SRR1474951 | GTEX | — | 0.967 |
| 5 | SRR1320093 | GTEX | — | 0.965 |
| 6 | SRR1324371 | GTEX | — | 0.965 |
| 7 | SRR1391922 | GTEX | — | 0.963 |
| 8 | SRR1399028 | GTEX | — | 0.963 |
| 9 | SRR1464451 | GTEX | — | 0.963 |
| 10 | SRR1362532 | GTEX | — | 0.961 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.434 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.314 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.278 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.235 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.144 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.067 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.025 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.012 | Inavolisib | — uncovered |